Intestinal Research

IBD
Concomitant ankylosing spondylitis can increase the risk of biologics or small molecule therapies to control inflammatory bowel disease: Yu Kyung Jun, Hyuk Yoon, Seong-Joon Koh, A Hyeon Kim, Kwang Woo Kim, Jun Won Park, Hyun Jung Lee, Hyoun Woo Kang, Jong Pil Im, Young Soo Park, Joo Sung Kim, on behalf of Seoul National University Inflammatory Bowel Disease Research Network (SIRN); Intest Res. 2023;21(2):244-251. Published online August 8, 2022; DOI: https://doi.org/10.5217/ir.2022.00057
Web of Science 1 Crossref 1; Full text PubReader ePub PDF Supplementary Material

Long-term safety and efficacy of adalimumab for intestinal Behçet's disease in the open label study following a phase 3 clinical trial: Nagamu Inoue, Kiyonori Kobayashi, Makoto Naganuma, Fumihito Hirai, Morio Ozawa, Dilek Arikan, Bidan Huang, Anne M. Robinson, Roopal B. Thakkar, Toshifumi Hibi; Intest Res. 2017;15(3):395-401. Published online June 12, 2017; DOI: https://doi.org/10.5217/ir.2017.15.3.395
Web of Science 31 Crossref 30; Full text PubReader ePub PDF

Biologics for the treatment of pyoderma gangrenosum in ulcerative colitis: K Arivarasan, Vaishali Bhardwaj, Sukrit Sud, Sanjeev Sachdeva, Amarender Singh Puri; Intest Res. 2016;14(4):365-368. Published online October 17, 2016; DOI: https://doi.org/10.5217/ir.2016.14.4.365
Web of Science 8 Crossref 11; Full text PubReader PDF

Search